ADCs remain in dealmakers’ sights. Here’s why
Antibody-drug conjugates remain red-hot in 2026’s biopharma M&A splurge. The overall ADC category will be worth $57 billion by 2032, according to Evaluate Pharma. Gilead’s $3 billion acquisition of Tubulis and Lilly’s of CrossBridge Bio are two of the latest deals. More will come as ADCs expand to hit new targets and carry new payloads. […]
Meet the Team: Paul Verdin
With over a decade at Evaluate under his belt, it seems remiss that we’ve not caught up with Paul Verdin, SVP, Head of Consulting and Analytics before now. In his role, he works closely with biotech and pharma companies on a range of projects from TPP assessment to indication selection. I finally pinned him down […]
